Your browser does not support iframes.
JERUSALEM--(BUSINESS WIRE)--Oct. 5, 2018--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced
today that it will release its third quarter 2018 financial results on
Thursday, November 1, 2018 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its third quarter 2018 results and overall
business environment. A Question & Answer session will follow this
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time):
For a list of other international toll-free numbers, click here.Passcode:
7193665A live webcast of the call will also be available on
Teva's website at: ir.tevapharm.com
Please log in at least 10 minutes prior to the conference call in order
to download the applicable software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until November 30, 2018, 9:00 a.m. ET by calling United
States 1 (866) 331-1332 or International +44 (0) 3333-009785; passcode: 7193665.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global
leader in generic medicines, with innovative treatments in select areas,
including CNS, pain and respiratory. We deliver high-quality generic
products and medicines in nearly every therapeutic area to address unmet
patient needs. We have an established presence in generics, specialty,
OTC and API, building on more than a century-old legacy, with a fully
integrated R&D function, strong operational base and global
infrastructure and scale. We strive to act in a socially and
environmentally responsible way. Headquartered in Israel, with
production and research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of patients.
Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2017, including the sections thereof captioned
"Risk Factors" and "Forward Looking Statements," and in our subsequent
quarterly reports on Form 10-Q and other filings with the Securities and
Exchange Commission, which are available at www.sec.gov
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise. You
are cautioned not to put undue reliance on these forward-looking
View source version on businesswire.com: https://www.businesswire.com/news/home/20181005005127/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.IR ContactsKevin
C. Mannix, (215) 591-8912Ran Meir, 972 (3) 926-7516orPR
ContactsUnited StatesElizabeth DeLuca, (267)
468-4329IsraelYonatan Beker, 972 (54) 888 5898